key: cord-0921269-7b5amqws authors: Fishman, Jay A.; Grossi, Paolo A. title: Novel Coronavirus‐19 (COVID‐19) in the immunocompromised transplant recipient: #Flatteningthecurve date: 2020-04-12 journal: Am J Transplant DOI: 10.1111/ajt.15890 sha: 38d75c3b66cdb293b531a6f90b87ef97da267411 doc_id: 921269 cord_uid: 7b5amqws COVID-19 has caused "closure of all schools and universities throughout Italy cinemas, theaters and discoteques are shut down as well.…(among) the few individuals who are out and about, I notice a lot of elbow bumping rather than both-cheek kissing and greater distance between people as they talk.…the trains between Florence and Rome …are largely empty." Lori Heatherington, Florence, Italy. ing has delayed understanding of the evolution of the epidemic. In the general population, the median incubation period is estimated at 5.1 days, and 97.5% of those who develop symptoms will do so within 11.5 days of infection. 1 Nasopharyngeal swab samples appear to be more sensitive for diagnosis than oropharyngeal and sputum samples; given sensitivity limitations, multiple negative assays are often used for ruleouts. 2 Viral shedding may persist for weeks (~20 days). Nosocomial transmission is common. R o (transmission kinetics) is ~2; this means that, without physical separation, 50% of the population must become immune to prevent spread in the community. Clinical variability is marked among normal hosts. 3 Some early screening for SARS-COV-2 may be negative, becoming positive subsequently. As for other viral infections, clinical manifestations include fever, cough, shortness of breath, myalgias, and sputum production. [4] [5] [6] [7] Dyspnea develops in over half of patients at a median of 8.0 days from illness onset. 5 20%-51% of patients have other comorbid medical conditions. The majority (~83%) have leukopenia and lymphopenia; patients admitted to the ICU were more likely to be older and have lower white cell and lymphocyte counts. 8 All patients developed abnormal radiographic findings including bilateral patchy shadows or ground glass opacities on chest CT. 8 https://medium.com/@nigam /highe r-co-infec tion-rates -in-covid 19-b2496 5088333). The overall case fatality rate for documented pneumonia has been reported variably as 1.4%-2% but may be lower in the absence of comorbidities (eg, 0.5%-1.0% or less). 4, 9 Significant variability seems to exist also in the clinical progression of disease between regions suggesting viral strain differences. Potential antiviral effects of immunosuppressants are untested. 11, 12 An unblinded study of respiratory viral loads with azithromycin and hydroxychloroquine provides a basis for trials which include data on inflammatory markers, viral loads, and diagnostic techniques. 13 Given the apparent role of inflammatory cytokines in COVID-19 infection, the benefits of more modest, individualized, reductions coupled with addition of immune modulation (eg, statins, modest dose corticosteroids or IL-6 inhibition therapies) might be consid- We do not yet know the incidence of asymptomatic infection and how long infectious virus persists during convalescence, notably among immunocompromised hosts. There is an urgent need to define viral pathogenesis, correlates of immunity, and biomarkers for the risk for progression. Cell entry is via the ACE2 receptor (on the X-chromosome) which is secreted in women and may reduce cellular entry -possibly accounting for gender differences in severe illness. The cytokine storm with infection appears greater in the elderly. Excess immunity may, therefore, increase the severity of disease and may mitigate against a rapid reduction in immunosuppression. Various antiviral therapies are under study; current data are often difficult to assess in the face of polypharmacy of antivirals (lopinavir/ritonavir, RNA polymerase inhibitor remdesivir, umifenovir/oseltamivir, chloroquine, angiotensin receptor blockers) and immune modulators (IL-6 inhibitors, corticosteroids, immunoglobulins, interferon-α or 1β). A vaccine is urgently needed but an effective clinical vaccine development is likely to take at least a year. In the meantime, public health measures include "social distancing" (reducing public contacts), school closings, working remotely and adequate paid sick leave (stay home when sick!). Clinical trials are essential to study the pathophysiology of COVID-19 infection and to develop effective therapies -for this and subsequent coronavirus outbreaks. We must avoid "cognitive bias by anecdote" and maintain clinical equipoise while striving to help our | 3 EDITORIAL patients. In the meantime, sharing of experiences worldwide provides a foundation for clinical care. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application Detection of SARS-CoV-2 in different types of clinical specimens A novel coronavirus emerging in china -key questions for impact assessment Clinical characteristics of coronavirus disease 2019 in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series A novel coronavirus from patients with pneumonia in China Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia SARS-CoV-2) infection in a renal transplant recipient: case report Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506 Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Coronavirus disease 2019: implications of emerging infections for transplantation Coronavirus disease 2019 and transplantation: a view from the inside A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19